Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Imv Inc. (IMV.TO)

Imv Inc. (IMV.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 296,831
  • Shares Outstanding, K 60,454
  • Annual Sales, $ 568 K
  • Annual Income, $ -27,365 K
  • 60-Month Beta 1.93
  • Price/Sales 448.95
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings -0.19 on 03/31/20
  • Next Earnings Date 05/14/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.12
  • Low Estimate -0.20
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.94 +68.71%
on 05/04/20
5.53 -10.31%
on 05/21/20
+1.63 (+48.95%)
since 04/24/20
3-Month
1.98 +150.51%
on 03/23/20
5.53 -10.31%
on 05/21/20
+1.19 (+31.56%)
since 02/25/20
52-Week
1.98 +150.51%
on 03/23/20
6.69 -25.86%
on 02/21/20
-0.38 (-7.12%)
since 05/24/19

Most Recent Stories

More News
IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies

--DPX-COVID-19 to utilize multi-target approach, to optimize immune response against virus' weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape

IMV.TO : 4.96 (+1.02%)
IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results

IMV Inc. (the "Company" or "IMV") (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced...

IMV.TO : 4.96 (+1.02%)
COVID-19 impact: Zika Virus Vaccine Market Analysis and Forecast to 2027 by Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview

MENAFN14052020007010847ID1100163051

GILD : 73.34 (-0.22%)
IMV.TO : 4.96 (+1.02%)
XON : 4.65 (-4.12%)
NLNK : 0.8900 (-12.75%)
Baculoviral IAP Repeat Containing Protein 5 Market 2020-2027: Biomics Biotechnologies Co Ltd, Bioneer Corp, Boehringer Ingelheim GmbH

In accordance with the study held by Ameco Research, the Baculoviral IAP Repeat Containing Protein 5 market was valued US$ XX Mn in 2019 and projected to reach US$ XX Mn in 2027 with a CAGR of XX.X% over...

IMV.TO : 4.96 (+1.02%)
STML : 11.90 (+0.25%)
IMV Inc. Announces Closing of $25.1 Million Private Placement

IMV Inc. ("IMV" or the "Company") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases...

IMV.TO : 4.96 (+1.02%)
IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020

IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases...

IMV.TO : 4.96 (+1.02%)
Vaccine Candidate to Prevent COVID-19: Fonds de solidarit� FTQ to Invest $7.5 Million in IMV

The Fonds de solidarit� FTQ (the "Fonds" will invest $7.5 million in IMV Inc. ("IMV") (Nasdaq: IMV); (TSX: IMV) to support the development of highly innovative immunotherapies and of a potential vaccine...

IMV : 3.53 (-2.75%)
IMV.TO : 4.96 (+1.02%)
IMV Announces Proposed $22.3 Million Private Placement

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the "Private Placement") of 7,797,203 units of the Company (each,...

IMV.TO : 4.96 (+1.02%)
IMV to Participate in Adelaide Capital's Virtual COVID & Healthcare Mini Conference

IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage biopharmaceutical company, today announced that Company's management will be participating in Adelaide Capital's Virtual COVID & Healthcare Mini Conference...

IMV.TO : 4.96 (+1.02%)
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results

IMV Inc. (the "Company" or "IMV") (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for...

IMV.TO : 4.96 (+1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 5.48
1st Resistance Point 5.19
Last Price 4.96
1st Support Level 4.67
2nd Support Level 4.44

See More

52-Week High 6.69
Last Price 4.96
Fibonacci 61.8% 4.89
Fibonacci 50% 4.34
Fibonacci 38.2% 3.78
52-Week Low 1.98

See More

Business Summary

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar